Strand Therapeutics Inc.

The end of each year brings a surge in venture capital funding announcements as biopharmaceutical companies and investors seek to close as many deals as possible before everyone takes off for the Dece

10 years ago, business talks involving Chinese pharma firms mostly focused on trying to get some attention from established biopharma giants and venture capital investors. The tone today is more on be

Venture capital investors have not taken the summer off, at least not during the first few weeks of June, continuing to support mega-rounds of $100m or more for biopharmaceutical companies with novel

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Takeda Teams With KSQ On Cancer Immunot